Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 2, 2012, Pages 146-155

  Pietu, Florence ^a,b   Guillaud, Olivier ^a   Walter, Thomas ^a,b   Vallin, Mélanie ^a,b   Hervieu, Valérie ^a,b   Scoazec, Jean Yves ^a,b   Dumortier, Jérôme ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONALCOHOLIC FATTY LIVER; PRURITUS; SCORING SYSTEM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FATTY LIVER; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; VITAMIN E; VITAMINS; YOUNG ADULT;

EID: 84858622244     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.10.011     Document Type: Article

References (45)

1. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
2. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
3. Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
4. Farrell G.C. Nonalcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol 2003, 18:124-138.
5. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:521-533.
6. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
7. Sanyal A.J. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005, 2:46-53.
8. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006, 40(3 Suppl 1):S17-S29.
9. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
10. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
11. Chitturi S., Farrell G.C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27-41.
12. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
13. Ratziu V., Bellentani S., Cortez-Pinto H., et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-384.
14. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23:1464-1467.
15. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
16. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
17. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
18. Balmer M.L., Siegrist K., Zimmermann A., et al. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int 2009, 29:1184-1188.
19. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
20. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
21. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408-1413.
22. Suzuki A., Lindor K., St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43:1060-1066.
23. Zelber-Sagi S., Kessler A., Brazowsky E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
24. Gary-Bobo M., Elachouri G., Gallas J.F., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007, 46:122-129.
25. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647-1654.
26. Klein S. Gastrointestinal surgery for obesity: a question of life and death and expertise. Gastroenterology 2006, 130:630.
27. Adams L.A., Angulo P. Treatment of nonalcoholic fatty liver disease. Postgrad Med J 2006, 82:315-322.
28. Uygun A., Kadayifci A., Isik A.T., et al. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
29. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
30. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
31. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008, 135:100-110.
32. Strauss R.S. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). National health and nutrition examination survey. J Pediatr 1999, 134:160-165.
33. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
34. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667-1672.
35. Kugelmas M., Hill D.B., Vivian B., et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38:413-419.
36. Ikegami T., Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res 2008, 38:123-131.
37. Chang C.Y., Argo C.K., Al-Osaimi A.M., et al. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2006, 40(Suppl 1):S51-S60.
38. Leuschner U.F., Lindenthal B., Herrmann G., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52:472-479.
39. Ratziu V., De Ledinghen V., Oberti F., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011, 54:1011-1019.
40. Angulo P., Dickson E.R., Therneau T.M., et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830-835.
41. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., Lindor K.D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558-1562.
42. Cullen S.N., Rust C., Fleming K., Edwards C., Beuers U., Chapman R.W. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008, 48:792-800.
43. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
44. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
45. Merriman R.B., Ferrell L.D., Patti M.G., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44:874-880.